FNY Investment Advisers’s Lakefront Biotherapeutics American Depositary Shares LKFT Stock Holding History

FNY Investment Advisers’s Portfolio LKFT Stock Details LKFT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q4	–	Sell	-3,000	Closed	-$127K	–	577
2022 Q3	$127K	Hold	3,000	–	–	0.09%	134
2022 Q2	$167K	Buy	+3,000	New	+$178K	0.12%	113
2020 Q2	–	Sell	-3,100	Closed	-$607K	–	469
2020 Q1	$607K	Buy	3,100 +2,332	+304%	+$502K	0.46%	49
2019 Q4	$158K	Buy	768 +48	+7%	+$8.87K	0.05%	284
2019 Q3	$109K	Buy	+720	New	+$118K	0.03%	281
2019 Q1	–	Sell	-5,000	Closed	-$458K	–	779
2018 Q4	$458K	Buy	+5,000	New	+$507K	0.16%	79

Other funds holding LKFT

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

EcoR1 Capital San Francisco, California $2.36B AUM 204.53% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Prosight Management Dallas, Texas $610M AUM 40.86% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

Finepoint Capital Boston, Massachusetts $1.95B AUM 45.61% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

Hudson Bay Capital Management Stamford, Connecticut $29B AUM 30.2% 1-Year Est. Return

FNY Investment Advisers's LKFT Position: Q4 2022 in Review

FNY Investment Advisers sold out of Lakefront Biotherapeutics American Depositary Shares (LKFT) in Q4 2022, closing a stake of 3,000 shares — an estimated $127K sold.

FNY Investment Advisers first reported a position in LKFT in Q4 2018 and held it in 6 quarters. The position peaked at $607K in Q1 2020. 75 funds tracked by Wall St. Rank hold LKFT as of Q4 2022.

FNY Investment Advisers reported no remaining Lakefront Biotherapeutics American Depositary Shares position as of Q4 2022 after selling out during the quarter.
FNY Investment Advisers sold 3,000 Lakefront Biotherapeutics American Depositary Shares shares in Q4 2022, an estimated $127K.
FNY Investment Advisers first reported a position in Lakefront Biotherapeutics American Depositary Shares in Q4 2018 and held it in 6 quarters.
FNY Investment Advisers's Lakefront Biotherapeutics American Depositary Shares position peaked at $607K in Q1 2020.
75 funds tracked by Wall St. Rank held Lakefront Biotherapeutics American Depositary Shares as of Q4 2022.

Based on FNY Investment Advisers's 13F filing for Q4 2022, filed 10 Jan 2023.